AI Assistant
Blog
Pricing
Log In
Sign Up
A phase II study of Zanubrutinib in combination with rituximab in patients with relapsed/refractory aggressive and indolent B-cell lymphoma
Details
Cite
Export
Add to List
This content is not available in your region!
Continue researching
here.
